Arcellx, Inc. (ACLX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arcellx, Inc. (“Arcellx” or the “Company”) (NASDAQ: ACLX). Investors who purchased Arcellx securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Arcellx has violated federal securities laws.
On June 19, 2023, Arcellx issued a press release “announc[ing] . . . that it has received notification from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on its CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).” Arcellx specified that “[t]he clinical hold was received on June 16, following a recent patient death. The company believes limitations on bridging therapy are a contributing factor and is working with FDA to amend the protocol to expand options for patients that are consistent with current clinical practice. The FDA has provided clearance to Arcellx to continue to dose patients who have undergone lymphodepletion.” On this news, Arcellx’s stock price fell $2.57 per share, or 7.18%, to close at $33.23 per share on June 20, 2023.
If you are aware of any facts relating to this investigation or purchased Arcellx shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.